These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 30266576)

  • 1. Clinical and metabolic characterization of obese subjects without non-alcoholic fatty liver: A targeted metabolomics approach.
    Feldman A; Eder SK; Felder TK; Paulweber B; Zandanell S; Stechemesser L; Schranz M; Strebinger G; Huber-Schönauer U; Niederseer D; Patsch W; Weghuber D; Tevini J; Datz C; Aigner E
    Diabetes Metab; 2019 Apr; 45(2):132-139. PubMed ID: 30266576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver.
    Feldman A; Eder SK; Felder TK; Kedenko L; Paulweber B; Stadlmayr A; Huber-Schönauer U; Niederseer D; Stickel F; Auer S; Haschke-Becher E; Patsch W; Datz C; Aigner E
    Am J Gastroenterol; 2017 Jan; 112(1):102-110. PubMed ID: 27527746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Characteristics and Metabolic Profiles of Non-Alcoholic Fatty Liver Disease (NAFLD) in Lean Patients and Their Comparison with Obese and Overweight NAFLD.
    Chakrabarty M; Jha AN; Sharma DJ
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity.
    Lonardo A; Mantovani A; Lugari S; Targher G
    Ann Hepatol; 2020; 19(4):359-366. PubMed ID: 32349939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obesity is more closely related with hepatic steatosis and fibrosis measured by transient elastography than metabolic health status.
    Huh JH; Kim KJ; Kim SU; Han SH; Han KH; Cha BS; Chung CH; Lee BW
    Metabolism; 2017 Jan; 66():23-31. PubMed ID: 27923446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolomic Salivary Signature of Pediatric Obesity Related Liver Disease and Metabolic Syndrome.
    Troisi J; Belmonte F; Bisogno A; Pierri L; Colucci A; Scala G; Cavallo P; Mandato C; Di Nuzzi A; Di Michele L; Delli Bovi AP; Guercio Nuzio S; Vajro P
    Nutrients; 2019 Jan; 11(2):. PubMed ID: 30691143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
    Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
    Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients.
    Sookoian S; Pirola CJ
    Aliment Pharmacol Ther; 2017 Jul; 46(2):85-95. PubMed ID: 28464369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lean non-alcoholic fatty liver disease patients had comparable total caloric, carbohydrate, protein, fat, iron, sleep duration and overtime work as obese non-alcoholic fatty liver disease patients.
    Li C; Guo P; Okekunle AP; Ji X; Huang M; Qi J; Jiang Y; Feng R; Li R
    J Gastroenterol Hepatol; 2019 Jan; 34(1):256-262. PubMed ID: 29949199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adiponectin-leptin ratio for the early detection of lean non-alcoholic fatty liver disease independent of insulin resistance.
    Lu CW; Yang KC; Chi YC; Wu TY; Chiang CH; Chang HH; Huang KC; Yang WS
    Ann Med; 2023 Dec; 55(1):634-642. PubMed ID: 36790383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolically healthy obesity is associated with an increased risk of diabetes independently of nonalcoholic fatty liver disease.
    Chang Y; Jung HS; Yun KE; Cho J; Ahn J; Chung EC; Shin H; Ryu S
    Obesity (Silver Spring); 2016 Sep; 24(9):1996-2003. PubMed ID: 27474900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolically Healthy Obesity and the Development of Nonalcoholic Fatty Liver Disease.
    Chang Y; Jung HS; Cho J; Zhang Y; Yun KE; Lazo M; Pastor-Barriuso R; Ahn J; Kim CW; Rampal S; Cainzos-Achirica M; Zhao D; Chung EC; Shin H; Guallar E; Ryu S
    Am J Gastroenterol; 2016 Aug; 111(8):1133-40. PubMed ID: 27185080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity.
    Ampuero J; Aller R; Gallego-Durán R; Banales JM; Crespo J; García-Monzón C; Pareja MJ; Vilar-Gómez E; Caballería J; Escudero-García D; Gomez-Camarero J; Calleja JL; Latorre M; Albillos A; Salmeron J; Aspichueta P; Lo Iacono O; Francés R; Benlloch S; Fernández-Rodríguez C; García-Samaniego J; Estévez P; Andrade RJ; Turnes J; Romero-Gómez M;
    Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1260-1270. PubMed ID: 30353552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolomic profiling identifies potential pathways involved in the interaction of iron homeostasis with glucose metabolism.
    Stechemesser L; Eder SK; Wagner A; Patsch W; Feldman A; Strasser M; Auer S; Niederseer D; Huber-Schönauer U; Paulweber B; Zandanell S; Ruhaltinger S; Weghuber D; Haschke-Becher E; Grabmer C; Rohde E; Datz C; Felder TK; Aigner E
    Mol Metab; 2017 Jan; 6(1):38-47. PubMed ID: 28123936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Difference in lifestyle and metabolic profile of non-alcoholic fatty liver disease with raised alanine amino-transferases between obese and non-overweight subjects.
    Sharma M; Kulkarni A; Kumar P; Nori VB; Jagtap N; Gupta R; Reddy DN; Rao PN
    Sci Rep; 2020 Sep; 10(1):15232. PubMed ID: 32943747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolically healthy versus unhealthy obesity and risk of fibrosis progression in non-alcoholic fatty liver disease.
    Kim Y; Chang Y; Cho YK; Ahn J; Shin H; Ryu S
    Liver Int; 2019 Oct; 39(10):1884-1894. PubMed ID: 31226232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease.
    Del Ben M; Polimeni L; Carnevale R; Bartimoccia S; Nocella C; Baratta F; Loffredo L; Pignatelli P; Violi F; Angelico F
    BMC Gastroenterol; 2014 Apr; 14():81. PubMed ID: 24758604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk stratification of non-alcoholic fatty liver disease across body mass index in a community basis.
    Huang JF; Tsai PC; Yeh ML; Huang CF; Huang CI; Hsieh MH; Dai CY; Yang JF; Chen SC; Yu ML; Chuang WL; Chang WY
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):89-96. PubMed ID: 30952479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic fatty liver disease as a sentinel marker for the development of diabetes mellitus in non-obese subjects.
    Kim SS; Cho HJ; Kim HJ; Kang DR; Berry JR; Kim JH; Yang MJ; Lim SG; Kim S; Cheong JY; Cho SW
    Dig Liver Dis; 2018 Apr; 50(4):370-377. PubMed ID: 29398414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.